Loading stock data…
AEON
$0.89-0.03 (-3.58%)
Market ClosedLast close May 1
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AEON Biopharma, Inc. in the Healthcare sector is trading at $0.89. The stock is currently 39% below its 52-week high of $1.45, remaining 6.3% below its 200-day moving average. Technical signals show neutral RSI of 53 and bearish MACD signal, explaining why AEON maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.89
Potential Upside
5%
Whystock Fair Value$0.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$27.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.73
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
71.28%
Volume
Today's trading volume
74,036
Recent News
Aeon Biopharma announces FDA feedback after Type 2a meeting
Aeon Biopharma (AEON) announced feedback from the FDA following a biosimilar biological product development Type 2a meeting. During the meeting, held in January, the FDA reviewed the company’s proposed analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback supporting the company’s planned analytical development approach. The agency acknowledged the scientific challenges associated with characterizing a 900 kDa botulinum neurotoxin complex, provided constructive
An Intrinsic Calculation For Aeon Co. (M) Bhd. (KLSE:AEON) Suggests It's 42% Undervalued
Key Insights Aeon (M) Bhd's estimated fair value is RM1.89 based on 2 Stage Free Cash Flow to Equity Aeon (M) Bhd's...
Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
The Returns At Aeon (M) Bhd (KLSE:AEON) Aren't Growing
What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Aeon Co. (M) Bhd.'s (KLSE:AEON) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 7.9% over the past three months, it is easy to disregard Aeon (M) Bhd (KLSE:AEON). However, the...